Data Regarding Micro Needle Intradermal Delivery Of VaxGen, Inc.'s Anthrax Vaccine Presented At American Association of Pharmaceutical Scientists Meeting

BRISBANE, Calif., Nov. 8 /PRNewswire-FirstCall/ -- WHAT: VaxGen, Inc. announced today a new pre-clinical study presented at the American Association of Pharmaceutical Sciences in Nashville, TN to compare the dosing and pharmacologic benefits of micro needle-based intradermal (ID) delivery of recombinant protective antigen (rPA) to intramuscular (IM) injection. WHEN: Poster presentation from 8 a.m. to noon EST Tuesday, November 8, 2005 WHERE: The American Association of Pharmaceutical Scientists (AAPS) Annual Meeting The Tennessee Ballroom, Gaylord Opryland Resort & Convention Center, Nashville, TN HOW: To view a copy of the poster, "Dose Sparing Benefits of Microneedle-based Intradermal Delivery of Bacillus anthracis Recombinant Protective Antigen," please visit the company's web site at: http://www.vaxgen.com . About VaxGen

VaxGen, Inc. is a biopharmaceutical company engaged in the development, manufacture and commercialization of biologic products for the prevention and treatment of human infectious diseases, including anthrax, smallpox and Meningitis B. The company has been awarded an $877.5 million U.S. government contract to provide 75 million doses of its recombinant anthrax vaccine for civilian biodefense. Based in Brisbane, Calif., VaxGen operates a wholly owned manufacturing facility in California and owns 22% of Celltrion, Inc., a South Korean operation established to provide contract manufacturing to the global pharmaceutical industry. For more information, please visit the company's web site at: http://www.vaxgen.com .

(Logo: http://www.newscom.com/cgi-bin/prnh/19991112/VAXGENLOGO )

Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/19991112/VAXGENLOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk,photodesk@prnewswire.comVaxGen, Inc.

CONTACT: Paul Laland of VaxGen, Inc., +1-650-624-1041

Back to news